DexCom vs MannKind: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

DexCom Inc (DXCM)

Q3 202622 Jun – 14 Sep 2026

▲3▼1

DexCom gains on FDA clearance, strong Q2, and expanded coverage

FDA clears Stelo for young children The FDA cleared DexCom's Stelo biosensor for children aged 2 and up, opening a new market and supporting the stock.
This is a new regulatory win that expands the addressable market.
Q2 revenue up 13%, guidance raised Q2 revenue rose 13% to $1.31 billion, leading DexCom to raise its 2026 revenue and margin guidance, a sign of strong business momentum.
This is a new financial update that directly boosts investor confidence.
Investor Day and G7 rollout lift shares DexCom's Investor Day sent shares up 25%, and the G7 15 Day rollout progressed, with major PBM coverage now reaching over 7 million non-insulin Type 2 patients.
These are new events that drove the stock higher during the quarter.
Abbott competition intensifies Abbott's FreeStyle Libre topped $2 billion in Q2 sales, and the FDA approved Abbott's Libre Duo, the first U.S. wearable tracking both glucose and ketones, potentially pressuring DexCom's pricing and market share.
This is a new competitive threat that could weigh on DexCom's future growth.

August 20262 Aug – 14 Sep 2026

▲3▼1

DexCom's Strong Q2 and G7 Rollout Drive Gains, but Abbott Competition Looms

Q2 Beat and Raised 2026 Outlook DexCom reported Q2 revenue up 13% to $1.31 billion and raised its full-year revenue and margin guidance, citing manufacturing efficiencies and the G7 15 Day sensor. This directly boosts investor confidence in future profits, pushing the stock up.
This is the core fundamental news that explains the stock's recent strength and improved outlook.
G7 15 Day Rollout and Reimbursement Progress DexCom is on track to convert nearly half of its U.S. customers to the G7 15 Day system by year-end, with coverage from the four largest PBMs covering over 7 million non-insulin Type 2 patients. This expands the market and supports long-term growth.
It shows a concrete driver of future revenue and margin expansion, which is key to the bull case.
Abbott's New Dual Ketone-Glucose Wearable Approved The FDA approved Abbott's Libre Duo 10 Day, the first U.S. wearable to continuously track both glucose and ketones. This could make Abbott's product more attractive and intensify competition, potentially pressuring DexCom's market share and pricing.
It introduces a new competitive threat that could cap DexCom's upside and is a real counterweight to the positive news.
Analyst Upgrades and Fair Value Increase Several analysts raised their price targets to $88–$96, lifting DexCom's fair value estimate to $91.64, after strong Q2 results and margin upside. This reflects growing optimism and can attract more investors, supporting the stock price.
It shows external validation of the company's improved prospects, which influences investor sentiment and demand for the stock.

Latest2 Aug – 14 Sep 2026

▲3▼1

DexCom's Strong Q2 and G7 Rollout Drive Gains, but Abbott Competition Looms

Q2 Beat and Raised 2026 Outlook DexCom reported Q2 revenue up 13% to $1.31 billion and raised its full-year revenue and margin guidance, citing manufacturing efficiencies and the G7 15 Day sensor. This directly boosts investor confidence in future profits, pushing the stock up.
This is the core fundamental news that explains the stock's recent strength and improved outlook.
G7 15 Day Rollout and Reimbursement Progress DexCom is on track to convert nearly half of its U.S. customers to the G7 15 Day system by year-end, with coverage from the four largest PBMs covering over 7 million non-insulin Type 2 patients. This expands the market and supports long-term growth.
It shows a concrete driver of future revenue and margin expansion, which is key to the bull case.
Abbott's New Dual Ketone-Glucose Wearable Approved The FDA approved Abbott's Libre Duo 10 Day, the first U.S. wearable to continuously track both glucose and ketones. This could make Abbott's product more attractive and intensify competition, potentially pressuring DexCom's market share and pricing.
It introduces a new competitive threat that could cap DexCom's upside and is a real counterweight to the positive news.
Analyst Upgrades and Fair Value Increase Several analysts raised their price targets to $88–$96, lifting DexCom's fair value estimate to $91.64, after strong Q2 results and margin upside. This reflects growing optimism and can attract more investors, supporting the stock price.
It shows external validation of the company's improved prospects, which influences investor sentiment and demand for the stock.

July 202622 Jun – 31 Jul 2026

▲3▼1

DexCom's growth story gets FDA boost, raised guidance, but Abbott competition looms

FDA clears Stelo for kids, expanding market DexCom won FDA clearance for its Stelo glucose biosensor in children aged 2 and older who don't use insulin, opening a new patient group. This expands the potential customer base and supports future sales growth, which can lift the stock as investors see a bigger runway.
This is a new regulatory win that directly expands DexCom's addressable market and is a key positive catalyst.
DexCom raises 2026 revenue outlook after strong Q2 DexCom reported Q2 revenue of $1.31 billion, up 13%, and raised full-year 2026 revenue guidance to $5.18–$5.25 billion. It also lifted margin guidance. This shows the business is growing faster than expected, which typically pushes the stock up.
This is a fresh earnings report with raised guidance, a major positive driver for the stock.
Abbott's CGM growth and new sensor intensify competition Abbott's FreeStyle Libre CGM sales topped $2 billion in Q2 and grew 9.5%, and it won CE Mark for a new dual glucose-ketone sensor. Abbott's expansion into the large Type 2 market could pressure DexCom's pricing and market share, a real headwind.
This highlights the main competitive threat that could cap DexCom's upside and is a recurring negative theme.
Investor Day reassures on long-term growth DexCom's management presented robust growth targets through 2030 at its Investor Day, helping drive a 25% share price increase. The event shifted sentiment positively as investors gained confidence in the long-term pipeline and market penetration potential.
This explains a major positive sentiment shift and is a new event that boosted the stock.

22 Jun – 31 Jul 2026

▲3▼1

DexCom's growth story gets FDA boost, raised guidance, but Abbott competition looms

FDA clears Stelo for kids, expanding market DexCom won FDA clearance for its Stelo glucose biosensor in children aged 2 and older who don't use insulin, opening a new patient group. This expands the potential customer base and supports future sales growth, which can lift the stock as investors see a bigger runway.
This is a new regulatory win that directly expands DexCom's addressable market and is a key positive catalyst.
DexCom raises 2026 revenue outlook after strong Q2 DexCom reported Q2 revenue of $1.31 billion, up 13%, and raised full-year 2026 revenue guidance to $5.18–$5.25 billion. It also lifted margin guidance. This shows the business is growing faster than expected, which typically pushes the stock up.
This is a fresh earnings report with raised guidance, a major positive driver for the stock.
Abbott's CGM growth and new sensor intensify competition Abbott's FreeStyle Libre CGM sales topped $2 billion in Q2 and grew 9.5%, and it won CE Mark for a new dual glucose-ketone sensor. Abbott's expansion into the large Type 2 market could pressure DexCom's pricing and market share, a real headwind.
This highlights the main competitive threat that could cap DexCom's upside and is a recurring negative theme.
Investor Day reassures on long-term growth DexCom's management presented robust growth targets through 2030 at its Investor Day, helping drive a 25% share price increase. The event shifted sentiment positively as investors gained confidence in the long-term pipeline and market penetration potential.
This explains a major positive sentiment shift and is a new event that boosted the stock.

MannKind Corp (MNKD)

Q3 20269 Jul – 6 Aug 2026

▲4▼1

MannKind's pipeline wins and record sales offset dilution and royalty threat

Afrezza pediatric approval drives 20% gain The FDA approved Afrezza, MannKind's inhaled insulin, for children aged 6 and up with diabetes. This opens a new market of over 350,000 young patients, and the stock has already risen about 20% since the news. Analysts see more upside ahead.
This is a major new approval that expands the market for MannKind's flagship product and has already boosted the stock.
Competitor Tresmi threatens Tyvaso DPI royalty United Therapeutics introduced Tresmi, a competing inhaler for the same condition as Tyvaso DPI. MannKind earns a 9% royalty on Tyvaso DPI sales, which brought in $32.7 million last quarter. If Tresmi takes market share, that royalty income could shrink, hurting MannKind's profits.
This is a new competitive threat that could reduce a significant and reliable revenue stream for MannKind.
$50 million private placement dilutes shares but funds CVR MannKind raised $50 million by selling new shares and warrants to investors led by Frazier Life Sciences. This brings in cash to fund a $45 million payment tied to the Furoscix ReadyFlow approval, but it also increases the number of shares outstanding, which can lower the value of each existing share.
This financing is a key capital event that affects MannKind's cash position and share count, with both positive and negative implications.
Furoscix ReadyFlow approved and launched The FDA approved Furoscix ReadyFlow, an at-home autoinjector for fluid overload in heart failure and kidney disease. This adds a new product to MannKind's lineup and triggered a $45 million payment to the original developer. Early sales are growing quickly, up 43% from the prior quarter.
This is a new product approval that diversifies revenue and has already started contributing to growth.
Inhaled nintedanib shows positive Phase 1b results MannKind's inhaled nintedanib for idiopathic pulmonary fibrosis (IPF) passed a mid-stage safety test, with no serious side effects. A larger Phase 2 trial is now enrolling patients. If successful, this could become a major new product, but it is still years from market.
This pipeline progress adds long-term growth potential and validates MannKind's inhalation technology.
Record Q2 revenue and all 2026 catalysts achieved MannKind reported second-quarter revenue of $109.4 million, up 43% from a year ago, driven by strong product sales and royalties. The company hit all three of its 2026 goals: Afrezza pediatric approval, Furoscix ReadyFlow approval, and positive nintedanib data. It ended the quarter with $161 million in cash.
This earnings report confirms strong financial performance and execution, which supports the stock's value.

July 20269 Jul – 6 Aug 2026

▲4▼1

MannKind's pipeline wins and record sales offset dilution and royalty threat

Afrezza pediatric approval drives 20% gain The FDA approved Afrezza, MannKind's inhaled insulin, for children aged 6 and up with diabetes. This opens a new market of over 350,000 young patients, and the stock has already risen about 20% since the news. Analysts see more upside ahead.
This is a major new approval that expands the market for MannKind's flagship product and has already boosted the stock.
Competitor Tresmi threatens Tyvaso DPI royalty United Therapeutics introduced Tresmi, a competing inhaler for the same condition as Tyvaso DPI. MannKind earns a 9% royalty on Tyvaso DPI sales, which brought in $32.7 million last quarter. If Tresmi takes market share, that royalty income could shrink, hurting MannKind's profits.
This is a new competitive threat that could reduce a significant and reliable revenue stream for MannKind.
$50 million private placement dilutes shares but funds CVR MannKind raised $50 million by selling new shares and warrants to investors led by Frazier Life Sciences. This brings in cash to fund a $45 million payment tied to the Furoscix ReadyFlow approval, but it also increases the number of shares outstanding, which can lower the value of each existing share.
This financing is a key capital event that affects MannKind's cash position and share count, with both positive and negative implications.
Furoscix ReadyFlow approved and launched The FDA approved Furoscix ReadyFlow, an at-home autoinjector for fluid overload in heart failure and kidney disease. This adds a new product to MannKind's lineup and triggered a $45 million payment to the original developer. Early sales are growing quickly, up 43% from the prior quarter.
This is a new product approval that diversifies revenue and has already started contributing to growth.
Inhaled nintedanib shows positive Phase 1b results MannKind's inhaled nintedanib for idiopathic pulmonary fibrosis (IPF) passed a mid-stage safety test, with no serious side effects. A larger Phase 2 trial is now enrolling patients. If successful, this could become a major new product, but it is still years from market.
This pipeline progress adds long-term growth potential and validates MannKind's inhalation technology.
Record Q2 revenue and all 2026 catalysts achieved MannKind reported second-quarter revenue of $109.4 million, up 43% from a year ago, driven by strong product sales and royalties. The company hit all three of its 2026 goals: Afrezza pediatric approval, Furoscix ReadyFlow approval, and positive nintedanib data. It ended the quarter with $161 million in cash.
This earnings report confirms strong financial performance and execution, which supports the stock's value.

Latest9 Jul – 6 Aug 2026

▲4▼1

MannKind's pipeline wins and record sales offset dilution and royalty threat

Afrezza pediatric approval drives 20% gain The FDA approved Afrezza, MannKind's inhaled insulin, for children aged 6 and up with diabetes. This opens a new market of over 350,000 young patients, and the stock has already risen about 20% since the news. Analysts see more upside ahead.
This is a major new approval that expands the market for MannKind's flagship product and has already boosted the stock.
Competitor Tresmi threatens Tyvaso DPI royalty United Therapeutics introduced Tresmi, a competing inhaler for the same condition as Tyvaso DPI. MannKind earns a 9% royalty on Tyvaso DPI sales, which brought in $32.7 million last quarter. If Tresmi takes market share, that royalty income could shrink, hurting MannKind's profits.
This is a new competitive threat that could reduce a significant and reliable revenue stream for MannKind.
$50 million private placement dilutes shares but funds CVR MannKind raised $50 million by selling new shares and warrants to investors led by Frazier Life Sciences. This brings in cash to fund a $45 million payment tied to the Furoscix ReadyFlow approval, but it also increases the number of shares outstanding, which can lower the value of each existing share.
This financing is a key capital event that affects MannKind's cash position and share count, with both positive and negative implications.
Furoscix ReadyFlow approved and launched The FDA approved Furoscix ReadyFlow, an at-home autoinjector for fluid overload in heart failure and kidney disease. This adds a new product to MannKind's lineup and triggered a $45 million payment to the original developer. Early sales are growing quickly, up 43% from the prior quarter.
This is a new product approval that diversifies revenue and has already started contributing to growth.
Inhaled nintedanib shows positive Phase 1b results MannKind's inhaled nintedanib for idiopathic pulmonary fibrosis (IPF) passed a mid-stage safety test, with no serious side effects. A larger Phase 2 trial is now enrolling patients. If successful, this could become a major new product, but it is still years from market.
This pipeline progress adds long-term growth potential and validates MannKind's inhalation technology.
Record Q2 revenue and all 2026 catalysts achieved MannKind reported second-quarter revenue of $109.4 million, up 43% from a year ago, driven by strong product sales and royalties. The company hit all three of its 2026 goals: Afrezza pediatric approval, Furoscix ReadyFlow approval, and positive nintedanib data. It ended the quarter with $161 million in cash.
This earnings report confirms strong financial performance and execution, which supports the stock's value.